Respiratory syncytial virus infection provides protection against severe acute respiratory syndrome coronavirus challenge.
Stacey M HartwigAbby OdleLok-Yin Roy WongDavid K MeyerholzStanley PerlmanSteven M VargaPublished in: Journal of virology (2024)
Severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus are respiratory viruses that are a major health burden worldwide. Severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus frequently have peak seasonal outbreaks during the winter months, and are capable of causing severe respiratory disease, often leading to hospitalization. The 2019 pandemic brought attention to the importance of understanding how co-circulating viruses can impact the disease severity of other respiratory viruses. It is known that many hospitalized patients are undergoing multiple viral infections at once, yet not much has been studied to understand the impact this has on other respiratory viruses or patients. How co-circulating viruses impact one another can provide critical knowledge for future interventions of hospitalized patients and potential vaccination strategies.
Keyphrases
- respiratory syndrome coronavirus
- respiratory syncytial virus
- sars cov
- coronavirus disease
- healthcare
- end stage renal disease
- chronic kidney disease
- public health
- genetic diversity
- ejection fraction
- respiratory tract
- physical activity
- early onset
- climate change
- human health
- patient reported outcomes
- risk assessment
- risk factors